Lung Cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 9, 2011, Pages 1412-1415

  Nakagawa, Kazuo ^a   Kondo, Haruhiko ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Adjuvant chemotherapy; Cisplatin; NSCLC; Personalized care; PORT; UFT

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; UFT;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; POSTOPERATIVE CARE; PREDICTIVE VALUE;

EID: 81855169527     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995.
2. Scagliotti GV, Fossati R, Scagliotti GV, et al.: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or III A non-small-cell lung cancer. J Natl Cancer Inst 95: 1453-1461, 2003. (Pubitemid 37279330)
3. Waller D, Peake MD, Stephens RJ, et al.: Chemotherapy for patients with non-small cell lung cancer: The surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26: 173-182, 2004. (Pubitemid 38759943)
4. The International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350: 351-360, 2004.
5. Winton T, Livingston R, Johnson D, et al.: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352: 2589-2597, 2005. (Pubitemid 41007845)
6. Douillard JY, Rosell R, De Lena M, et al.: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage I B-III A non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 7: 719-727, 2006. (Pubitemid 44283661)
7. Pignon JP, Tribodet H, Scagliotti GV, et al.: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26: 3552-3559, 2008.
8. NSCLC Meta-analyses Collaborative Group: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375: 1267-1277, 2010.
9. Wada H, Hitomi S, Teramatsu T, et al.: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 14: 1048-1054, 1996. (Pubitemid 26105508)
10. Kato H, Ichinose Y, Ohta M, et al.: A randomised trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004. (Pubitemid 38501140)
11. Hamada C, Tanaka F, Ohta M, et al.: Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small cell lung cancer. J Clin Oncol 23: 4999-5006, 2005. (Pubitemid 46224006)
12. Strauss GM, Herndon JE 2nd, Maddaus MA, et al.: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer CALGB9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26: 5043-5051, 2008.
13. Butts CA, Ding K, Seymour L, et al.: Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage I B and II non-small cell lung cancer: Updated survival analysis of JBR. 10. J Clin Oncol 28: 29-34, 2010.
14. Hamada C, Tsuboi M, Ohta M, et al.: Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage I A non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials. J Thorac Oncol 4: 1511-1516, 2009.
15. Douillard JY, Tribodet H, Aubert D, et al.: LACE Collaborative Group. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol 5: 220-228, 2010.
16. PORT Meta-analysis Trialists Group: Postoperative radiotherapy in nonsmall-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352: 257-263, 1998.
17. Lally BE, Zelterman D, Colasanto JM, et al.: Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 24: 2998-3006, 2006. (Pubitemid 46638932)
18. Douillard JY, Rosell R, De Lena M, et al.: Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or III A non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 72: 695-701, 2008.
19. Ettinger DS, Akerley W, Bepler G, et al.: NCCN Non-Small Cell Lung Cancer Panel Members. Non-small cell lung cancer. J Natl Compr Canc Netw 8: 740-801, 2010.
20. Lim E, Baldwin D, Beckles M, et al.: British Thoracic Society; Society for Cardiothoracic Surgery in Great Britain and Ireland. Guidelines on the radical Guidelines on the radical management of patients with lung cancer. Thorax 65(suppl 3): iii1-27, 2010.
21. Crinò L, Weder W, van Meerbeeck J, et al.: ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (suppl 5): v103-v115, 2010.
22. Zheng Z, Chen T, Li X, et al.: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356: 800-808, 2007. (Pubitemid 46294612)